This is a cohort of people who inject drugs with chronic HCV infection. Patients are seen at a low-threshold clinic. All patients are offered treatment for HCV and subsequently followed for to years~Inclusion Consenting patients older than 18 years attending the low threshold HCV clinic in Oslo~The primary aims are to assess the efficacy (SVR rate) of DAA treatment among PWID treated in a low-threshold primary care setting (Work Package 1) and to estimate the incidence HCV reinfection f~The secondary aims are to:~Evaluate adherence to DAA treatment (Work Package 1)~Identify factors associated with SVR and adherence (Work Package 1)~Characterize reinfection using next generation sequencing (Work Package 2)~Identify factors associated with reinfection (Work Package 2)~Evaluate changes in recent injecting risk behaviours longitudinally (Work Package 2)~Identify factors associated with changes in risk behaviours (Work Package 2)~The hypothesis is that high SVR rates and good treatment adherence will be achieved in PWID treated for HCV infection in a low-threshold primary health care setting. Further,it is anticipated that the incidence of reinfection will be 5-10/100 PY and associated with younger age, low education level and ongoing injecting risk behaviours.~The study will include 300 patients and are close to achieving that aim the summer of 2019
This is a cohort of people who inject drugs with chronic HCV infection. Patients are seen at a low-threshold clinic. All patients are offered treatment for HCV and subsequently followed for to years